Program
Methoxydimethyltryptamines
Also written as “5 Methoxy N,N Dimethyltryptamine”, “GH001” and “BMND08”.
Its studies are mostly in Depressive Disorder, Treatment-Resistant · Mood Disorders · Depression, Postpartum · Bipolar Disorder, led by 3 companies.
Drug pageMethoxydimethyltryptamines: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GH Research Ireland | 90 open or running | phase 2since Nov 17, 2020 | Nov 12, 2020 | none ahead |
| Biomind Labsits history only | 10 open or running | phase 2since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 1since Aug 24, 2021 | Aug 24, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GH Research Ireland only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04640831 · 22 enrolled · Netherlands
- Nov 17, 2020Phase 2 study in Depressive Disorder, Treatment-ResistantNCT04698603 · 16 enrolled · Netherlands
- Nov 18, 2021Phase 1 study in Healthy VolunteersNCT05163691 · 46 enrolled · Netherlands
- Feb 23, 2023Phase 1 study in Healthy VolunteersNCT05753956 · 64 enrolled · Netherlands
- Mar 22, 20232 phase 2 studiesNCT05800860, NCT05804708
- Apr 20, 2023Phase 2 study in Bipolar DisorderNCT05839509 · 6 enrolled · Germany, Netherlands, United Kingdom
- Jun 28, 2024Phase 1 study in Healthy VolunteersNCT06511947 · 71 enrolled · United Kingdom
- Apr 1, 2026Phase 1 study in Healthy AdultNCT07540494 · 13 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 GH Research Ireland leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07540494Healthy Adult · United States | 1 | Completed | May 8, 2026 | 13 |
| NCT06511947Healthy Volunteers · United Kingdom | 1 | Terminated | Mar 23, 2026 | 71 |
| NCT05839509Bipolar Disorder · Germany, Netherlands, United Kingdom | 2 | Terminated | Nov 13, 2024 | 6 |
| NCT05804708Depression, Postpartum · Netherlands, United Kingdom | 2 | Terminated | Aug 2, 2024 | 10 |
| NCT05800860Depressive Disorder, Treatment-Resistant · Czechia, Germany, Ireland and more | 2 | Completed | Oct 4, 2024 | 81 |
| NCT05753956Healthy Volunteers · Netherlands | 1 | Completed | Nov 29, 2023 | 64 |
| NCT05163691Healthy Volunteers · Netherlands | 1 | Completed | Oct 23, 2021 | 46 |
| NCT04698603Depressive Disorder, Treatment-Resistant · Netherlands | 2 | Completed | Nov 6, 2021 | 16 |
| NCT04640831Healthy Volunteers · Netherlands | 1 | Completed | Oct 4, 2019 | 22 |
How it is read
Names in the registry
- “5 Methoxy N,N Dimethyltryptamine”, 6 entries
- “GH001”, 3 entries
- “BMND08”, 1 entry
- “5-MeO-DMT”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Treatment-Resistant, 2 studies
- Mood Disorders, 1 study
- Depression, Postpartum, 1 study
- Bipolar Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.